november 2009

In the summer of 1987, I graduated from a public high school in Austin, Texas, and headed northeast to attend Yale. I then spent nearly 15 years studying at various universities—the London School of Economics, the University of Oxford, Harvard, and finally Yale Law School—picking up a string of degrees along the way. Today, I teach at Yale Law, where my students unnervingly resemble my younger self: They are, overwhelmingly, products of professional parents and high-class universities. I pass on to them the advantages that my own teachers bestowed on me. They, and I, owe our prosperity and our caste to meritocracy.

Two decades ago, when I started writing about economic inequality, meritocracy seemed more likely a cure than a cause. Meritocracy’s early advocates championed social mobility. In the 1960s, for instance, Yale President Kingman Brewster brought meritocratic admissions to the university with the express aim of breaking a hereditary elite. Alumni had long believed that their sons had a birthright to follow them to Yale; now prospective students would gain admission based on achievement rather than breeding. Meritocracy—for a time—replaced complacent insiders with talented and hardworking outsiders.

Every morning of my Joe Rogan experience began the same way Joe Rogan begins his: with the mushroom coffee.

It’s a pour-and-stir powder made from lion’s mane and chaga—“two rock-star mushrooms,” according to Joe—and it’s made by a company called Four Sigmatic, a regular advertiser on Joe Rogan’s wildly popular podcast. As a coffee lover, the mere existence of mushroom coffee offends me. (“I’ll have your most delicious thing, made from your least delicious things, please,” a friend said, scornfully.) But it tastes fine, and even better after another cup of actual coffee.

Next, I took several vitamin supplements from a company called Onnit, whose core philosophy is “total human optimization” and whose website sells all kinds of wicked-cool fitness gear—a Darth Vader kettlebell ($199.95); a 50-foot roll of two-and-a-half-inch-thick battle rope ($249.95); a 25-pound quad mace ($147.95), which according to one fitness-equipment site is a weapon dating back to 11th-century Persia. I stuck to the health products, though, because you know how it goes—you buy one quad mace and soon your apartment is filled with them. I stirred a packet of Onnit Gut Health powder into my mushroom coffee, then downed an enormous pair of Alpha Brain pills, filled with nootropics to help with “memory and focus.”

I haven’t seen Justice Hans Linde in more than a decade, but I thought of him last Saturday, when I found myself locked in a science museum with frightened parents and children while neofascist thugs marched by. Hans was a child in Weimar Germany; I suspect he would have known how I was feeling.

The museum was the Oregon Museum of Science and Industry, in Portland. The occasion was a rally organized by the Proud Boys, an all-male group that exalts “Western values” and promotes Islamophobia. Other affiliated groups joined in—a loose conglomeration of racists, chauvinists, and just plain thugs. Some of them were connected to the Unite the Right rally in Charlottesville, Virginia, two years ago, at which a right-wing marcher drove his car into a crowd of counterprotesters, killing a woman named Heather Heyer. The Proud Boys aren’t from Portland, but they have selected the Rose City as the site for their rallies, threats, and clashes with local “antifa,” or antifascist activists. The rally Saturday was nominally to demand that Portland suppress the antifa groups so that the Proud Boys can march unopposed whenever they choose.

Through the 2016 campaign, I posted a series called “Trump Time Capsule” in this space. The idea was to record, in real time, what was known about Donald Trump’s fitness for office—and to do so not when people were looking back on our era but while the Republican Party was deciding whether to line up behind him and voters were preparing to make their choice.

The series reached 152 installments by election day. I argued that even then there was no doubt of Trump’s mental, emotional, civic, and ethical unfitness for national leadership. If you’re hazy on the details, the series is (once again) here.

That background has equipped me to view Trump’s performance in office as consistently shocking but rarely surprising. He lied on the campaign trail, and he lies in office. He insulted women, minorities, “the other” as a candidate, and he does it as a president. He led “lock her up!” cheers at the Republican National Convention and he smiles at “send them back!” cheers now. He did not know how the “nuclear triad” worked then, and he does not know how tariffs work now. He flared at perceived personal slights when they came from Senator John McCain, and he does so when they come from the Prime Minister of Denmark. He is who he was.

They walk among us, endowed with a superpower invisible to the naked eye. Before an important early meeting, they never have to forgo a shower and settle for dry shampoo and a baby wipe. They rarely wake with a jolt at 10 in the morning and stare groggily at a phone screen with five missed calls and texts that say, “You on your way? ETA?”

They are people who wake up early—naturally. Not just “early” in the sense of a perky-at-8-a.m. spouse. These are the people whose bodies rouse them at 5:30 a.m. or earlier—some even at hours others are just going to sleep. And new research a decade in the making suggests that the extremely early risers among us might be more common than anyone expected.

Louis J. Ptáček, a professor of neurology at the University of California at San Francisco School of Medicine and an author of the study, got the idea to research these super-larks about 20 years ago, when one of his colleagues introduced him to a 69-year-old woman who was regularly waking up at 1 or 2 a.m. Many people tend to wake up earlier as they age, but even when this woman was in her 30s she was waking up at 4 a.m.

Every week, The Friendship Files features a conversation between The Atlantic’s Julie Beck and two or more friends, exploring the history and significance of their relationship.

This week she talks with four men, all active in the evangelical Church of the Nazarene, who assign themselves reading and then have an annual retreat where they discuss faith, death, and how to live well. In this interview, they tell their origin story, share their reading list, and explain the particular importance of friendship for adult men.

The Friends

Randy Beckum, 65, a pastor with the Church of the Nazarene, who lives in Honolulu, Hawaii
Gary Morsch, 68, an emergency-room doctor who lives in Bucyrus, Kansas
Dean Nelson, 65, director of the journalism program at Point Loma Nazarene University, in San Diego, California
Rick Power, 64, a district administrator for the Church of the Nazarene who lives in Kailua, Hawaii

Yesterday, President Donald Trump canceled a meeting with the new Danish prime minister, Mette Frederiksen, because she refuses to discuss the sale of Greenland. Greenland used to be a Danish colony but now belongs to the people of Greenland—the Danish government could not sell the island even if it wanted to. Trump likely did not know that Denmark is one of America’s most reliable allies. Danish troops, for example, fought alongside U.S. forces in Iraq and Afghanistan and suffered 50 fatalities, and Danish forces were among the earliest to join the fight against the Islamic State.

Many Americans may laugh off Trump’s latest outrage, but Trump crossed an important line. It is one thing to float a cockamamie idea that no one believes is serious or will go anywhere. “Let’s buy Greenland!” Yes, very funny. A good distraction from the economy, the failure to deal with white supremacy, White House staff problems, or whatever is the news of the day. It is quite another to use leverage and impose costs on Denmark in pursuit of that goal—and make no mistake, canceling a presidential visit is using leverage and imposing costs. What’s next, refusing to exempt Denmark from various tariffs because it won’t discuss Greenland? Musing on Twitter that America’s defense commitments to Denmark are conditional on the negotiation? Intellectual justifications from Trump-friendly publications, citing previous purchase proposals and noting Greenland’s strategic value and abundance of natural resources? (That last one has already happened.)

Fate sometimes has an acute sense of irony. This morning, the political donor and philanthropist David Koch died. Koch’s father was an early, prominent supporter of the limited-government, red-baiting John Birch Society. Koch ran for vice president as a Libertarian in 1980, but he and his brother Charles eventually shifted their focus to pushing the Republican Party in an aggressively small-government, low-regulation direction. They had remarkable success, but had serious disagreements with the current Republican president, Donald Trump.

The same morning Koch died, Trump tweeted:

… better off without them. The vast amounts of money made and stolen by China from the United States, year after year, for decades, will and must STOP. Our great American companies are hereby ordered to immediately start looking for an alternative to China, including bringing ...

— Donald J. Trump (@realDonaldTrump) August 23, 2019

President Donald Trump said on Wednesday that the government will purchase “a lot” of the drug esketamine, a derivative of ketamine.

Though ketamine is known as a recreational hallucinogen, Trump asserted that a new nasal-spray derivative would be of great benefit to veterans with depression. As he left the White House for a veterans’ conference in Kentucky, he told reporters that he had instructed the Department of Veterans Affairs to make a large purchase—overriding a recent decision by the doctors who manage the hospitals’ formulary of which drugs are to be prescribed.

“There’s a product that’s made right now that just came out by Johnson & Johnson which has a tremendously positive—pretty short-term, but nevertheless positive—effect,” Trump said. But that statement is contrary to the evidence. A review by the Food and Drug Administration of what limited studies have been done with esketamine found mixed results, leaving many scientists unsure if the drug is indeed effective and safe. Just last week, the agency published a report that said the drug was not reliably better than placebo.